Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Jun 15;97(12):2833–2841. doi: 10.1172/JCI118739

Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures.

L M Williams 1, D L Gibbons 1, A Gearing 1, R N Maini 1, M Feldmann 1, F M Brennan 1
PMCID: PMC507377  PMID: 8675695

Abstract

We have previously hypothesized that the pro-inflammatory cytokine TNF alpha has a pivotal role in the pathogenesis of rheumatoid arthritis (RA). It mediates its effects by cross-linking surface p55 TNF receptors (TNF-R), which can be proteolytically cleaved to yield soluble fragments. Upon binding TNF alpha soluble TNF-R (sTNF-R) can inhibit its function. We investigated the enzymatic nature of the proteases involved in TNF-R cleavage, and found that this process is blocked by a synthetic inhibitor of matrix metallo-proteinase activity (MMP), BB-2275. Inhibition of TNF-R cleavage was observed in a number of different cell types, as detected by retention of surface bound TNF receptor and by less sTNF-R released into the cell supernatant. The augmentation of surface TNF-R expression was of biological relevance as TNF alpha-mediated necrosis of human KYM.1D4 rhabdosarcoma cells was enhanced approximately 15-fold in the presence of BB-2275. The addition of BB-2275 to rheumatoid synovial membrane cell cultures totally inhibited MMP activity and also significantly reduced the levels of soluble TNF alpha (P < 0.006), p55 sTNF-R (P < 0.006), and p75 sTNF-R (P < 0.004). Paradoxically, despite the reduction in soluble TNF alpha levels, the production of IL-1 beta, IL-6, and IL-8, cytokines whose production was previously demonstrated to be inhibited by the addition of neutralizing anti-TNF alpha antibody were not down-regulated by BB-2275. These results raise the interesting possibility that a close relationship exits between the enzyme(s) which process membrane-bound TNF alpha, and those involved in surface TNF-R cleavage. Furthermore our observations suggest that hydroxamate inhibitors of MMP activity which block TNF alpha secretion and TNF-R cleavage may not modulate down-stream effects of TNA alpha, and as such suggest that the precise specificity of these compounds will be highly relevant to their clinical efficacy in inflammatory diseases.

Full Text

The Full Text of this article is available as a PDF (362.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aderka D., Engelmann H., Maor Y., Brakebusch C., Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992 Feb 1;175(2):323–329. doi: 10.1084/jem.175.2.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brennan F. M., Chantry D., Jackson A., Maini R., Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989 Jul 29;2(8657):244–247. doi: 10.1016/s0140-6736(89)90430-3. [DOI] [PubMed] [Google Scholar]
  3. Brennan F. M., Gibbons D. L., Cope A. P., Katsikis P., Maini R. N., Feldmann M. TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action. Scand J Immunol. 1995 Jul;42(1):158–165. doi: 10.1111/j.1365-3083.1995.tb03639.x. [DOI] [PubMed] [Google Scholar]
  4. Brennan F. M., Gibbons D. L., Mitchell T., Cope A. P., Maini R. N., Feldmann M. Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur J Immunol. 1992 Jul;22(7):1907–1912. doi: 10.1002/eji.1830220734. [DOI] [PubMed] [Google Scholar]
  5. Brennan F. M., Maini R. N., Feldmann M. TNF alpha--a pivotal role in rheumatoid arthritis? Br J Rheumatol. 1992 May;31(5):293–298. doi: 10.1093/rheumatology/31.5.293. [DOI] [PubMed] [Google Scholar]
  6. Brinckerhoff C. E. Joint destruction in arthritis: metalloproteinases in the spotlight. Arthritis Rheum. 1991 Sep;34(9):1073–1075. doi: 10.1002/art.1780340902. [DOI] [PubMed] [Google Scholar]
  7. Butler D. M., Maini R. N., Feldmann M., Brennan F. M. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw. 1995 Jul-Dec;6(4):225–230. [PubMed] [Google Scholar]
  8. Butler D. M., Scallon B., Meager A., Kissonerghis M., Corcoran A., Chernajovsky Y., Feldmann M., Ghrayeb J., Brennan F. M. TNF receptor fusion proteins are effective inhibitors of TNF-mediated cytotoxicity on human KYM-1D4 rhabdomyosarcoma cells. Cytokine. 1994 Nov;6(6):616–623. doi: 10.1016/1043-4666(94)90049-3. [DOI] [PubMed] [Google Scholar]
  9. Chandler S., Coates R., Gearing A., Lury J., Wells G., Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett. 1995 Dec 15;201(3):223–226. doi: 10.1016/0304-3940(95)12173-0. [DOI] [PubMed] [Google Scholar]
  10. Chu C. Q., Field M., Feldmann M., Maini R. N. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991 Sep;34(9):1125–1132. doi: 10.1002/art.1780340908. [DOI] [PubMed] [Google Scholar]
  11. Conway J. G., Wakefield J. A., Brown R. H., Marron B. E., Sekut L., Stimpson S. A., McElroy A., Menius J. A., Jeffreys J. J., Clark R. L. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J Exp Med. 1995 Aug 1;182(2):449–457. doi: 10.1084/jem.182.2.449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cope A. P., Aderka D., Doherty M., Engelmann H., Gibbons D., Jones A. C., Brennan F. M., Maini R. N., Wallach D., Feldmann M. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 1992 Oct;35(10):1160–1169. doi: 10.1002/art.1780351008. [DOI] [PubMed] [Google Scholar]
  13. Cope A. P., Gibbons D. L., Aderka D., Foxwell B. M., Wallach D., Maini R. N., Feldmann M., Brennan F. M. Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells. Cytokine. 1993 May;5(3):205–212. doi: 10.1016/1043-4666(93)90006-q. [DOI] [PubMed] [Google Scholar]
  14. Crowe P. D., Walter B. N., Mohler K. M., Otten-Evans C., Black R. A., Ware C. F. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med. 1995 Mar 1;181(3):1205–1210. doi: 10.1084/jem.181.3.1205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Deleuran B. W., Chu C. Q., Field M., Brennan F. M., Mitchell T., Feldmann M., Maini R. N. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum. 1992 Oct;35(10):1170–1178. doi: 10.1002/art.1780351009. [DOI] [PubMed] [Google Scholar]
  16. DiMartino M. J., High W., Galloway W. A., Crimmin M. J. Preclinical antiarthritic activity of matrix metalloproteinase inhibitors. Ann N Y Acad Sci. 1994 Sep 6;732:411–413. doi: 10.1111/j.1749-6632.1994.tb24769.x. [DOI] [PubMed] [Google Scholar]
  17. DiStefano P. S., Chelsea D. M., Schick C. M., McKelvy J. F. Involvement of a metalloprotease in low-affinity nerve growth factor receptor truncation: inhibition of truncation in vitro and in vivo. J Neurosci. 1993 Jun;13(6):2405–2414. doi: 10.1523/JNEUROSCI.13-06-02405.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Downing J. R., Roussel M. F., Sherr C. J. Ligand and protein kinase C downmodulate the colony-stimulating factor 1 receptor by independent mechanisms. Mol Cell Biol. 1989 Jul;9(7):2890–2896. doi: 10.1128/mcb.9.7.2890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Bijl H., Woody J. N. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1125–1127. doi: 10.1016/s0140-6736(94)90632-7. [DOI] [PubMed] [Google Scholar]
  20. Engelberts I., Möller A., Schoen G. J., van der Linden C. J., Buurman W. A. Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res. 1991 Apr;10(1-2):69–76. [PubMed] [Google Scholar]
  21. Engelmann H., Aderka D., Rubinstein M., Rotman D., Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem. 1989 Jul 15;264(20):11974–11980. [PubMed] [Google Scholar]
  22. Gearing A. J., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A. H., Drummond A. H., Galloway W. A., Gilbert R., Gordon J. L. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature. 1994 Aug 18;370(6490):555–557. doi: 10.1038/370555a0. [DOI] [PubMed] [Google Scholar]
  23. Goodwin R. G., Friend D., Ziegler S. F., Jerzy R., Falk B. A., Gimpel S., Cosman D., Dower S. K., March C. J., Namen A. E. Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell. 1990 Mar 23;60(6):941–951. doi: 10.1016/0092-8674(90)90342-c. [DOI] [PubMed] [Google Scholar]
  24. Gray P. W., Barrett K., Chantry D., Turner M., Feldmann M. Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7380–7384. doi: 10.1073/pnas.87.19.7380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Gullberg U., Lantz M., Lindvall L., Olsson I., Himmler A. Involvement of an Asn/Val cleavage site in the production of a soluble form of a human tumor necrosis factor (TNF) receptor. Site-directed mutagenesis of a putative cleavage site in the p55 TNF receptor chain. Eur J Cell Biol. 1992 Aug;58(2):307–312. [PubMed] [Google Scholar]
  26. Haworth C., Brennan F. M., Chantry D., Turner M., Maini R. N., Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol. 1991 Oct;21(10):2575–2579. doi: 10.1002/eji.1830211039. [DOI] [PubMed] [Google Scholar]
  27. Hwang C., Gatanaga M., Granger G. A., Gatanaga T. Mechanism of release of soluble forms of tumor necrosis factor/lymphotoxin receptors by phorbol myristate acetate-stimulated human THP-1 cells in vitro. J Immunol. 1993 Nov 15;151(10):5631–5638. [PubMed] [Google Scholar]
  28. Imamura K., Spriggs D., Kufe D. Expression of tumor necrosis factor receptors on human monocytes and internalization of receptor bound ligand. J Immunol. 1987 Nov 1;139(9):2989–2992. [PubMed] [Google Scholar]
  29. Joyce D. A., Gibbons D. P., Green P., Steer J. H., Feldmann M., Brennan F. M. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol. 1994 Nov;24(11):2699–2705. doi: 10.1002/eji.1830241119. [DOI] [PubMed] [Google Scholar]
  30. Katsikis P. D., Chu C. Q., Brennan F. M., Maini R. N., Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med. 1994 May 1;179(5):1517–1527. doi: 10.1084/jem.179.5.1517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Knight C. G., Willenbrock F., Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992 Jan 27;296(3):263–266. doi: 10.1016/0014-5793(92)80300-6. [DOI] [PubMed] [Google Scholar]
  32. Kruys V., Kemmer K., Shakhov A., Jongeneel V., Beutler B. Constitutive activity of the tumor necrosis factor promoter is canceled by the 3' untranslated region in nonmacrophage cell lines; a trans-dominant factor overcomes this suppressive effect. Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):673–677. doi: 10.1073/pnas.89.2.673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Lantz M., Malik S., Slevin M. L., Olsson I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine. 1990 Nov;2(6):402–406. doi: 10.1016/1043-4666(90)90048-x. [DOI] [PubMed] [Google Scholar]
  34. Leeuwenberg J. F., Jeunhomme T. M., Buurman W. A. Slow release of soluble TNF receptors by monocytes in vitro. J Immunol. 1994 Apr 15;152(8):4036–4043. [PubMed] [Google Scholar]
  35. McGeehan G. M., Becherer J. D., Bast R. C., Jr, Boyer C. M., Champion B., Connolly K. M., Conway J. G., Furdon P., Karp S., Kidao S. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature. 1994 Aug 18;370(6490):558–561. doi: 10.1038/370558a0. [DOI] [PubMed] [Google Scholar]
  36. Meager A. A cytotoxicity assay for tumour necrosis factor using a human rhabdomyosarcoma cell line. J Immunol Methods. 1991 Nov 5;144(1):141–143. doi: 10.1016/0022-1759(91)90239-c. [DOI] [PubMed] [Google Scholar]
  37. Mohler K. M., Sleath P. R., Fitzner J. N., Cerretti D. P., Alderson M., Kerwar S. S., Torrance D. S., Otten-Evans C., Greenstreet T., Weerawarna K. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 1994 Jul 21;370(6486):218–220. doi: 10.1038/370218a0. [DOI] [PubMed] [Google Scholar]
  38. Mosley B., Beckmann M. P., March C. J., Idzerda R. L., Gimpel S. D., VandenBos T., Friend D., Alpert A., Anderson D., Jackson J. The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell. 1989 Oct 20;59(2):335–348. doi: 10.1016/0092-8674(89)90295-x. [DOI] [PubMed] [Google Scholar]
  39. Novick D., Cohen B., Rubinstein M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell. 1994 May 6;77(3):391–400. doi: 10.1016/0092-8674(94)90154-6. [DOI] [PubMed] [Google Scholar]
  40. Novick D., Engelmann H., Wallach D., Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med. 1989 Oct 1;170(4):1409–1414. doi: 10.1084/jem.170.4.1409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Porteu F., Brockhaus M., Wallach D., Engelmann H., Nathan C. F. Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. J Biol Chem. 1991 Oct 5;266(28):18846–18853. [PubMed] [Google Scholar]
  42. Porteu F., Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med. 1990 Aug 1;172(2):599–607. doi: 10.1084/jem.172.2.599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Rubin L. A., Kurman C. C., Fritz M. E., Biddison W. E., Boutin B., Yarchoan R., Nelson D. L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985 Nov;135(5):3172–3177. [PubMed] [Google Scholar]
  44. Seckinger P., Isaaz S., Dayer J. M. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem. 1989 Jul 15;264(20):11966–11973. [PubMed] [Google Scholar]
  45. Smith C. A., Davis T., Anderson D., Solam L., Beckmann M. P., Jerzy R., Dower S. K., Cosman D., Goodwin R. G. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science. 1990 May 25;248(4958):1019–1023. doi: 10.1126/science.2160731. [DOI] [PubMed] [Google Scholar]
  46. Stetler-Stevenson W. G., Krutzsch H. C., Wacher M. P., Margulies I. M., Liotta L. A. The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation. J Biol Chem. 1989 Jan 25;264(3):1353–1356. [PubMed] [Google Scholar]
  47. Symons J. A., Eastgate J. A., Duff G. W. Purification and characterization of a novel soluble receptor for interleukin 1. J Exp Med. 1991 Nov 1;174(5):1251–1254. doi: 10.1084/jem.174.5.1251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. de Waal Malefyt R., Abrams J., Bennett B., Figdor C. G., de Vries J. E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991 Nov 1;174(5):1209–1220. doi: 10.1084/jem.174.5.1209. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES